219 related articles for article (PubMed ID: 27286443)
1. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
Smith TR; Cote DJ; Jane JA; Laws ER
J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
[TBL] [Abstract][Full Text] [Related]
2. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
[TBL] [Abstract][Full Text] [Related]
3. Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up.
Müller HL; Gebhardt U; Schröder S; Pohl F; Kortmann RD; Faldum A; Zwiener I; Warmuth-Metz M; Pietsch T; Calaminus G; Kolb R; Wiegand C; Sörensen N;
Horm Res Paediatr; 2010; 73(3):175-80. PubMed ID: 20197669
[TBL] [Abstract][Full Text] [Related]
4. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
Nguyen Quoc A; Beccaria K; González Briceño L; Pinto G; Samara-Boustani D; Stoupa A; Beltrand J; Besançon A; Thalassinos C; Puget S; Blauwblomme T; Alapetite C; Bolle S; Doz F; Grill J; Dufour C; Bourdeaut F; Abbou S; Guerrini-Rousseau L; Leruste A; Brabant S; Cavadias I; Viaud M; Boddaert N; Polak M; Kariyawasam D
J Clin Endocrinol Metab; 2023 Jul; 108(8):1929-1936. PubMed ID: 36794424
[TBL] [Abstract][Full Text] [Related]
5. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
[TBL] [Abstract][Full Text] [Related]
6. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.
Karavitaki N; Warner JT; Marland A; Shine B; Ryan F; Arnold J; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 May; 64(5):556-60. PubMed ID: 16649976
[TBL] [Abstract][Full Text] [Related]
7. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis.
Alotaibi NM; Noormohamed N; Cote DJ; Alharthi S; Doucette J; Zaidi HA; Mekary RA; Smith TR
World Neurosurg; 2018 Jan; 109():487-496.e1. PubMed ID: 28987837
[TBL] [Abstract][Full Text] [Related]
8. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
[TBL] [Abstract][Full Text] [Related]
9. Patients with craniopharyngiomas: therapeutical difficulties with growth hormone.
Cannavò S; Marini F; Trimarchi F
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):56-60. PubMed ID: 19020388
[TBL] [Abstract][Full Text] [Related]
10. Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database.
Price DA; Jönsson P
Acta Paediatr Suppl; 1996 Oct; 417():83-5. PubMed ID: 9055921
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome in children with recurrent craniopharyngioma after primary surgery.
Kalapurakal JA; Goldman S; Hsieh YC; Tomita T; Marymont MH
Cancer J; 2000; 6(6):388-93. PubMed ID: 11131489
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of sellar and suprasellar tumors in children treated with hGH--relation to immunohistochemical study on GH receptor.
Uchino Y; Saeki N; Iwadate Y; Yasuda T; Konda S; Watanabe T; Wada K; Kazukawa I; Higuchi Y; Iuchi T; Tatsuno I; Yamaura A
Endocr J; 2000 Mar; 47 Suppl():S33-6. PubMed ID: 10890179
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of recombinant human growth hormone in turner syndrome.
Bolar K; Hoffman AR; Maneatis T; Lippe B
J Clin Endocrinol Metab; 2008 Feb; 93(2):344-51. PubMed ID: 18000090
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database).
Darendeliler F; Karagiannis G; Wilton P; Ranke MB; Albertsson-Wikland K; Anthony Price D; On Behalf Of The Kigs International Board
Acta Paediatr; 2006 Oct; 95(10):1284-90. PubMed ID: 16982503
[TBL] [Abstract][Full Text] [Related]
16. Postoperative pituitary hormonal disturbances and hormone replacement therapy time and dosage in children with craniopharyngiomas.
Li GM; Sun XJ; Shao P
Chin Med J (Engl); 2008 Oct; 121(20):2077-82. PubMed ID: 19080279
[TBL] [Abstract][Full Text] [Related]
17. Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement.
Yuen KCJ; Mattsson AF; Burman P; Erfurth EM; Camacho-Hubner C; Fox JL; Verhelst J; Geffner ME; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):768-777. PubMed ID: 29029108
[TBL] [Abstract][Full Text] [Related]
18. [Effect of recombinant human growth hormone therapy on metabolic parameters in patients with craniopharyngioma].
Mao JF; Wang X; Xiong SY; Zheng JJ; Yu BQ; Nie M; Wu XY; Qi ST
Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(42):3286-3290. PubMed ID: 29141371
[No Abstract] [Full Text] [Related]
19. Craniopharyngiomas in children: recurrence, reoperation and outcome.
Vinchon M; Dhellemmes P
Childs Nerv Syst; 2008 Feb; 24(2):211-7. PubMed ID: 17786455
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
Holmer H; Ekman B; Björk J; Nordstöm CH; Popovic V; Siversson A; Erfurth EM
Eur J Endocrinol; 2009 Nov; 161(5):671-9. PubMed ID: 19667040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
